Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Neuropsychiatric disorders correction in Alzheimer's disease

Full Text:


Behavioral and neuropsychiatric symptoms occur in 80% of patients with Alzheimer's disease (AD) and represent one of the most common reasons for early hospitalization and increased treatment costs. It is believed that the development of mental disorders (MD) is a marker of a number of additional adverse outcomes in patients with AD. The disease is accompanied by the development of other behavioral disorders, the most unpleasant of which are agitation (excitation) and aggression. The article discusses the causes and factors that can provoke the development of MD in AD. Traditionally used pharmacotherapeutic methods for the treatment of MD in AD in this age group have limited efficacy and are characterized by high toxicity. Antipsychotics are often associated with serious side effects and increased mortality in patients with dementia. A clinical case of AD with the development of neuropsychiatric disorders is presented. We discuss the issue of nonpharmacological strategies that have been shown to be more effective than pharmacological treatment and have fewer side effects than antipsychotic pharmacotherapy. On the example of the given clinical case, modern approaches to the correction of such complications and the management of this group of patients are shown. It seems appropriate to use memantine (akatinol memantine) in patients with neuropsychiatric symptoms of AD. In clinical studies, memantine has shown a positive effect in terms of reducing the rate of deterioration of general, cognitive, functional and behavioral parameters compared with treatment with antipsychotics. The drug is characterized by a minimum number of side effects and a limited range of contraindications.

About the Author

N. N. Koberskaya
N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation

Department of Nervous Diseases and Neurosurgery, N. V. Sklifosovsky Institute of Clinical Medicine

11, Rossolimo St., Build. 1, Moscow 119021


1. Leroi I, Voulgari A, Breitner JC, Lyketsos CG. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry. 2003 Jan-Feb;11(1):83-91.

2. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989 Jan;25(1):39-48. doi: 10.1016/0006-3223(89)90145-5

3. Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R; National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group. Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain. 2010 Apr;133(Pt 4):1155-62. doi: 10.1093/brain/awq001. Epub 2010 Feb 10.

4. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998 Feb;46(2):210-5. doi: 10.1111/j.1532-5415.1998.tb02542.x

5. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005 Oct;62(10):1601-8. doi: 10.1001/archneur.62.10.1601

6. Cummings JL, Diaz C, Levy M, et al. Neuropsychiatric Syndromes in Neurodegenerative Disease: Frequency and Signficance. Semin Clin Neuropsychiatry. 1996 Oct;1(4):241-7. doi: 10.1053/SCNP00100241

7. Wilson RS, Tang Y, Aggarwal NT, et al. Hallucinations, cognitive decline, and death in Alzheimer's disease. Neuroepidemiology. 2006;26(2):68-75. doi: 10.1159/000090251. Epub 2005 Dec 13.

8. Bruen PD, McGeown WJ, Shanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain. 2008 Sep;131(Pt 9):2455-63. doi: 10.1093/brain/awn151. Epub 2008 Jul 11.

9. Mega MS, Lee L, Dinov ID, et al. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):167-71. doi: 10.1136/jnnp.69.2.167

10. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease Prospective analyses from the Predictors Study. Neurology. 1994 Dec;44(12):2300-7. doi: 10.1212/wnl.44.12.2300

11. Zwijsen SA, van der Ploeg E, Hertogh CM. Understanding the world of dementia. How do people with dementia experience the world? Int Psychogeriatr. 2016 Jul;28(7):1067-77. doi: 10.1017/S1041610216000351. Epub 2016 Mar 3.

12. Sweet RA, Nimgaonkar VL, Devlin B, et al. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002 Mar 26;58(6):907-11. doi: 10.1212/wnl.58.6.907

13. Hadjistavropoulos T, Herr K, Turk DC, et al. An interdisciplinary expert consensus statement on assessment of pain in older persons. Clin J Pain. 2007 Jan;23(1 Suppl):S1-43. doi: 10.1097/AJP.0b013e31802be869

14. Kolanowski A, Boltz M, Galik E, et al. Determinants of behavioral and psychological symptoms of dementia: A scoping review of the evidence. Nurs Outlook. 2017 Sep- Oct;65(5):515-29. doi: 10.1016/j.outlook.2017.06.006. Epub 2017 Jun 16.

15. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990 May;38(5):553-63. doi: 10.1111/j.1532-5415.1990.tb02407.x

16. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006 Mar;14(3):191-210. doi: 10.1097/01.JGP.0000200589.01396.6d

17. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012 Feb 23;344:e977. doi: 10.1136/bmj.e977

18. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007 Oct;164(10):1568-76; quiz 1623. doi: 10.1176/appi.ajp.2007.06101710

19. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015 May;72(5):438-45. doi: 10.1001/jamapsychiatry.2014.3018

20. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012 Jul;72(1):41-52. doi: 10.1002/ana.23557

21. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.

22. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015 Mar 2;350:h369. doi: 10.1136/bmj.h369

23. Smith M, Hall GR, Gerdner L, Buckwalter KC. Application of the Progressively Lowered Stress Threshold Model across the continuum of care. Nurs Clin North Am. 2006 Mar;41(1):57-81, vi. doi: 10.1016/j.cnur.2005.09.006

24. Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD003945. doi: 10.1002/14651858.CD003945.pub3. Update in: Cochrane Database Syst Rev. 2018 Oct 05;10:CD003945. doi: 10.1002/14651858.CD003945.pub4

25. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008191. doi: 10.1002/14651858.CD008191.pub2

26. Maust DT, Langa KM, Blow FC, Kales HC. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. Int J Geriatr Psychiatry. 2017 Feb;32(2):164-74. doi: 10.1002/gps.4452. Epub 2016 Feb 18.

27. Seitz DP, Gill SS, Herrmann N, et al. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr. 2013 Feb;25(2):185-203. doi: 10.1017/S1041610212001627. Epub 2012 Oct 19.

28. Ralph SJ, Espinet AJ. Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. J Alzheimers Dis Rep. 2018;2(1):1-26. doi: 10.3233/ADR-170042

29. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012 Sep;169(9):900-6. doi: 10.1176/appi.ajp.2012.12030342

30. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-94. doi: 10.1111/jgs.15767. Epub 2019 Jan 29.

31. Deuschl G, Maier W. S3-Leitlinie Demenzen. Deutsche Gesellschaft für Neurologie, Leitlinien für Diagnostik und Therapie in der Neurologie. 2016. Available from:

32. Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726. doi: 10.1002/14651858.CD007726.pub2

33. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20-7. doi: 10.1159/000102568. Epub 2007 May 10.

34. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin Interv Aging. 2009;4:367-77. doi: 10.2147/cia.s6666. Epub 2009 Oct 12.

35. Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008 Jan;42(1):32-8. doi: 10.1345/aph.1K372. Epub 2007 Dec 4.

36. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008 May;23(5):537-45. doi: 10.1002/gps.1949

37. Bullock R. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):23-9. doi: 10.1097/01.wad.0000201847.29836.a5

38. Cumbo E, Ligori LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. J Alzheimers Dis. 2014;39(3):477-85. doi: 10.3233/JAD-131190

39. Gitlin LN, Winter L, Vause Earland T, et al. The Tailored Activity Program to reduce behavioral symptoms in individuals with dementia: feasibility, acceptability, and replication potential. Gerontologist. 2009 Jun;49(3):428-39. doi: 10.1093/geront/gnp087. Epub 2009 May 6.

40. Abraha I, Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open. 2017 Mar 16;7(3):e012759. doi: 10.1136/bmjopen-2016-012759. Erratum in: BMJ Open. 2017 Jul 17;7(7):e012759corr1.

41. Caspar S, Davis ED, Douziech A, Scott DR. Nonpharmacological Management of Behavioral and Psychological Symptoms of Dementia: What Works, in What Circumstances, and Why? Innov Aging. 2018;2 (1):igy001. doi: 10.1093/geroni/igy001

42. Soril LJ, Leggett LE, Lorenzetti DL, et al. Effective use of the built environment to manage behavioural and psychological symptoms of dementia: a systematic review. PLoS One. 2014 Dec 17;9(12):e115425. doi: 10.1371/journal.pone.0115425

43. Wilson R, Collerton D, Freeston M, et al. Is Seeing Believing? The Process of Change During Cognitive-behavioural Therapy for Distressing Visual Hallucinations. Clin Psychol Psychother. 2016 Jul;23(4):285-97. doi: 10.1002/cpp.1962. Epub 2015 Jun 3.

44. Holroyd S, Sheldon-Keller A. A Study of Visual Hallucinations in Alzheimer's Disease. Am J Geriatr Psychiatry. 1995 Summer;3(3):198-205. doi: 10.1097/00019442-199522330-00003. Epub 2012 Aug 15.

45. Kontos P, Miller KL, Colobong R, et al. Elder-Clowning in Long-Term Dementia Care: Results of a Pilot Study. J Am Geriatr Soc. 2016 Feb;64(2):347-53. doi: 10.1111/jgs.13941

46. Husebo BS, Ballard C, Cohen-Mansfield J, et al. The response of agitated behavior to pain management in persons with dementia. Am J Geriatr Psychiatry. 2014 Jul;22(7):708-17. doi: 10.1016/j.jagp.2012.12.006. Epub 2013 Apr 20.

47. Petersen S, Houston S, Qin H, et al. The Utilization of Robotic Pets in Dementia Care. J Alzheimers Dis. 2017;55(2):569-74. doi: 10.3233/JAD-160703

48. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012 Sep;169(9):946-53. doi: 10.1176/appi.ajp.2012.11101529. Erratum in: Am J Psychiatry. 2013 Feb 1;170(2):227.

49. Dyer SM, Harrison SL, Laver K, et al. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2018 Mar;30(3):295-309. doi: 10.1017/S1041610217002344. Epub 2017 Nov 16.

50. Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010;30(2):161-78. doi: 10.1159/000316119. Epub 2010 Sep 10.

51. Jennings AA, Foley T, Walsh KA, et al. General practitioners' knowledge, attitudes, and experiences of managing behavioural and psychological symptoms of dementia: A mixed-methods systematic review. Int J Geriatr Psychiatry. 2018 Jun 13;33(9):1163-76. doi: 10.1002/gps.4918. Epub ahead of print.

52. Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5. doi: 10.1186/alzrt201. Epub 2013 Jul 8.

53. Ihl R, Bunevicius R, Frölich L, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Dementia. World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. Int J Psychiatry Clin Pract. 2015 Mar;19(1):2-7. doi: 10.3109/13651501.2014.961931. Epub 2014 Oct 18.

54. Craig C, Tannenbaum C, Ducruet T, Moride Y. Patterns of antipsychotic use among community-dwelling elderly patients with dementia: impact of regulatory warnings. Med Saf Glo Heal. 2016;5(129):2. doi: 10.4172/2574-0407.1000129

55. Norgaard A, Jensen-Dahm C, Gasse C, et al. Time trends in antipsychotic drug use in patients with dementia: a nationwide study. J Alzheimers Dis. 2016;49(1):211-20. doi: 10.3233/JAD-150481

56. Azermai M, Petrovic M, Elseviers MM, et al. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res Rev. 2012 Jan;11(1):78-86. doi: 10.1016/j.arr.2011.07.002. Epub 2011 Aug 10.

57. Miarons M, Cabib C, Baron FJ, Rofes L. Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms. Eur J Clin Pharmacol. 2017 Nov;73(11):1389-98. doi: 10.1007/s00228-017-2314-3. Epub 2017 Aug 5.


For citations:

Koberskaya N.N. Neuropsychiatric disorders correction in Alzheimer's disease. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):54-61. (In Russ.)

Views: 206

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)